Clinical trial
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
NCT00323323 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00323323 |
|---|---|
| Title | CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas |
| Official title | A Phase I Study of CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | CHOP, Alemtuzumab, Plasma Samples |
| Enrollment | 24 |
| Start date | Mar 1, 2004 |
| Primary completion | Aug 1, 2012 |
| Completion | Oct 1, 2016 |
| First posted | May 9, 2006 |
| Last update posted | Jan 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: